Anti NY-ESO-1 T Cells, Donor 401
Catalog Number: 1093
Lot Number: 4096NV18

Certificate of Analysis

Cell count 2 million per vial
Viability 86%
CD8+ 94%
CD8+NegTetramer+ 0.6%
CD8+NYESO-1Tetramer+ 31.4%
Sterility Negative for Bacteria, Yeast and Fungi

Donor Information

Donor ID 401
Age 29
Gender Female
Race Caucasian
Height 5'3"
Weight 277
ABO Type A negative

HLA typing

<table>
<thead>
<tr>
<th>Allele 1</th>
<th>Allele 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-A</td>
<td>*0201</td>
</tr>
<tr>
<td>HLA-B</td>
<td>*18</td>
</tr>
<tr>
<td>HLA-C</td>
<td>*03</td>
</tr>
<tr>
<td>HLA-DRB1</td>
<td>*03</td>
</tr>
</tbody>
</table>

Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1 and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures.
20,000 T cells were plated post-thaw in a 96-well round-bottom plate in the presence of 20,000 T2 cells, a B-LCL expressing HLA-A*0201 alone or in the presence of increasing concentrations of HLA-A*0201 restricted NY-ESO-1 peptide (SLLMWITQC) or HLA-A*0201 restricted CMVpp65 peptide (NLVPMVATV). After an overnight (18-24h) incubation period, supernatant was collected from each well. IFN-γ concentration was analyzed using the Meso Scale Discovery IFN-γ assay.